{"groups":[{"description":"During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.","id":"FG000","title":"Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG001","title":"Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG002","title":"Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab"},{"description":"During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG003","title":"Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG004","title":"Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG005","title":"Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG006","title":"Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG007","title":"Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"FG008","title":"Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab"},{"description":"During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"FG009","title":"Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"FG010","title":"Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"FG011","title":"Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 3.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"FG012","title":"Combination B Phase 1b: PF-04518600 3.0 mg/kg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"FG013","title":"Combination B Phase 2 NSCLC: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 2 participants with SCCHN received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"FG014","title":"Combination B Phase 2 SCCHN: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 50 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"FG015","title":"Combination C Phase 1b: PD 0360324 50 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 100 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG016","title":"Combination C Phase 1b: PD 0360324 100 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 150 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"FG017","title":"Combination C Phase 1b: PD 0360324 150 mg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"FG018","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"FG019","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"FG020","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"FG021","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"FG022","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"FG023","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 sub-cutaneous \\[SC\\] administered at weekly intervals, followed by 5 intra tumoral \\[IT\\] administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W. Phase 2 was not planned.","id":"FG024","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg + Avelumab"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus utomilumab 100 mg administered IV Q4W. Phase 2 was not planned.","id":"FG025","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + Utomilumab 100 mg"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus PF-04518600 at 0.3 mg/kg administered IV Q2W. Phase 2 was not planned.","id":"FG026","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + PF-04518600 0.3 mg/kg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"6"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"2"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"3"},{"groupId":"FG014","numSubjects":"2"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"2"},{"groupId":"FG022","numSubjects":"1"},{"groupId":"FG023","numSubjects":"1"},{"groupId":"FG024","numSubjects":"1"},{"groupId":"FG025","numSubjects":"2"},{"groupId":"FG026","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"1"},{"groupId":"FG019","numSubjects":"2"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"1"},{"groupId":"FG022","numSubjects":"1"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"Global deterioration of health status"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"19"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"21"},{"groupId":"FG005","numSubjects":"15"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"13"},{"groupId":"FG008","numSubjects":"6"},{"groupId":"FG009","numSubjects":"6"},{"groupId":"FG010","numSubjects":"8"},{"groupId":"FG011","numSubjects":"8"},{"groupId":"FG012","numSubjects":"6"},{"groupId":"FG013","numSubjects":"10"},{"groupId":"FG014","numSubjects":"20"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"3"},{"groupId":"FG017","numSubjects":"3"},{"groupId":"FG018","numSubjects":"11"},{"groupId":"FG019","numSubjects":"7"},{"groupId":"FG020","numSubjects":"11"},{"groupId":"FG021","numSubjects":"6"},{"groupId":"FG022","numSubjects":"9"},{"groupId":"FG023","numSubjects":"9"},{"groupId":"FG024","numSubjects":"4"},{"groupId":"FG025","numSubjects":"5"},{"groupId":"FG026","numSubjects":"5"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"2"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"1"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"3"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"2"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"1"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"1"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"1"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"1"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"Study terminated by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"No longer meets eligibility criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"35"},{"groupId":"FG005","numSubjects":"21"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"21"},{"groupId":"FG008","numSubjects":"11"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"12"},{"groupId":"FG012","numSubjects":"8"},{"groupId":"FG013","numSubjects":"14"},{"groupId":"FG014","numSubjects":"25"},{"groupId":"FG015","numSubjects":"10"},{"groupId":"FG016","numSubjects":"8"},{"groupId":"FG017","numSubjects":"6"},{"groupId":"FG018","numSubjects":"12"},{"groupId":"FG019","numSubjects":"12"},{"groupId":"FG020","numSubjects":"12"},{"groupId":"FG021","numSubjects":"12"},{"groupId":"FG022","numSubjects":"12"},{"groupId":"FG023","numSubjects":"11"},{"groupId":"FG024","numSubjects":"6"},{"groupId":"FG025","numSubjects":"7"},{"groupId":"FG026","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"35"},{"groupId":"FG005","numSubjects":"21"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"21"},{"groupId":"FG008","numSubjects":"11"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"12"},{"groupId":"FG012","numSubjects":"8"},{"groupId":"FG013","numSubjects":"14"},{"groupId":"FG014","numSubjects":"25"},{"groupId":"FG015","numSubjects":"10"},{"groupId":"FG016","numSubjects":"8"},{"groupId":"FG017","numSubjects":"6"},{"groupId":"FG018","numSubjects":"12"},{"groupId":"FG019","numSubjects":"12"},{"groupId":"FG020","numSubjects":"12"},{"groupId":"FG021","numSubjects":"12"},{"groupId":"FG022","numSubjects":"12"},{"groupId":"FG023","numSubjects":"11"},{"groupId":"FG024","numSubjects":"6"},{"groupId":"FG025","numSubjects":"7"},{"groupId":"FG026","numSubjects":"7"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"},{"groupId":"FG023","numSubjects":"0"},{"groupId":"FG024","numSubjects":"0"},{"groupId":"FG025","numSubjects":"0"},{"groupId":"FG026","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"35"},{"groupId":"FG005","numSubjects":"21"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"21"},{"groupId":"FG008","numSubjects":"11"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"12"},{"groupId":"FG011","numSubjects":"12"},{"groupId":"FG012","numSubjects":"8"},{"groupId":"FG013","numSubjects":"14"},{"groupId":"FG014","numSubjects":"25"},{"groupId":"FG015","numSubjects":"10"},{"groupId":"FG016","numSubjects":"8"},{"groupId":"FG017","numSubjects":"6"},{"groupId":"FG018","numSubjects":"12"},{"groupId":"FG019","numSubjects":"12"},{"groupId":"FG020","numSubjects":"12"},{"groupId":"FG021","numSubjects":"12"},{"groupId":"FG022","numSubjects":"12"},{"groupId":"FG023","numSubjects":"11"},{"groupId":"FG024","numSubjects":"6"},{"groupId":"FG025","numSubjects":"7"},{"groupId":"FG026","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"In this study participants were evaluated in 5 different combinations with avelumab: Combination A, B, C, D and F. Each combination was planned to be conducted in 2 phases: Phase 1b (lead-in phase) and Phase 2 (expansion phase). Phase 2 was conducted at the selected dose level of avelumab combination which was determined safe for participants in Phase 1b."}